Adverum Biotechnologies
Adverum Biotechnologies
ADVM
NASDAQ
6.94
USD
53.54%
About
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections.
Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 194.5K |
| Three Month Average Volume | 6.9M |
| High Low | |
| Fifty-Two Week High | 29.7 USD |
| Fifty-Two Week Low | 6.38 USD |
| Fifty-Two Week High Date | 08 Feb 2024 |
| Fifty-Two Week Low Date | 20 Jun 2024 |
| Price and Volume | |
| Current Price | 6.94 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -8.12% |
| Thirteen Week Relative Price Change | -18.13% |
| Twenty-Six Week Relative Price Change | -67.96% |
| Fifty-Two Week Relative Price Change | -68.17% |
| Year-to-Date Relative Price Change | -22.15% |
| Price Change | |
| One Day Price Change | 0.87% |
| Thirteen Week Price Change | -12.37% |
| Twenty-Six Week Price Change | -64.77% |
| Five Day Price Change | -5.19% |
| Fifty-Two Week Price Change | -60.11% |
| Year-to-Date Price Change | -7.81% |
| Month-to-Date Price Change | -6.47% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 8.22898 USD |
| Book Value Per Share (Most Recent Quarter) | 8.07793 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 8.22898 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 8.07793 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -7.20989 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.35706 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -11.62075 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -7.98907 USD |
| Normalized (Last Fiscal Year) | -11.60785 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -11.62075 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -7.98907 USD |
| Including Extraordinary Items (Last Fiscal Year) | -11.62075 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -7.98907 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 9.51623 USD |
| Cash Per Share (Most Recent Quarter) | 8.35667 USD |
| Cash Flow Per Share (Last Fiscal Year) | -11.06096 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -6.62983 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -6.19419 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -4,354 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -3,284.53% |
| Pretax Margin (5 Year) | -5,278.63% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -3,444.19% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -5,407.43% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -3,254.58% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -5,279.60% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -23.76% |
| Tangible Book Value (5 Year) | -16.13% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | 17.43% |
| Revenue Change (Trailing Twelve Months) | -100.00% |
| Revenue Per Share Growth | 6.33% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -0.02% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 71.66% |
| EPS Change (Trailing Twelve Months) | 40.09% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -173,827,000 |
| Net Debt (Last Fiscal Year) | -96,526,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 40 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 8 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -91,710,000 |
| Free Cash Flow (Trailing Twelve Months) | -89,123,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -48.68% |
| Return on Assets (Trailing Twelve Months) | -40.33% |
| Return on Assets (5 Year) | -36.39% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -88.43% |
| Return on Equity (Trailing Twelve Months) | -66.76% |
| Return on Equity (5 Year) | -47.96% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -55.24% |
| Return on Investment (Trailing Twelve Months) | -46.64% |
| Return on Investment (5 Year) | -39.04% |